Top Industry News

Novo Nordisk has announced an investment of EUR 432 million ($502 million) to expand its tableting facility in Monksland, Athlone, Ireland, to produce current and future Novo Nordisk glucagon-like peptide-1 (GLP-1) treatments. It provides Novo Nordisk with additional manufacturing capabilities for…

To boost its late-stage neuroscience pipeline, Novartis has completed its $12-billion acquisition of Avidity Biosciences, a bio/pharmaceutical company developing RNA therapeutics. The deal was announced in October 2025.  Avidity is developing RNA therapeutics and antibody oligonucleotide conjugates (AOCs) for treating rare genetic neuromuscular…

GSK has completed its acquisition of RAPT Therapeutics, a South San Franciso, California-based, clinical-stage bio/pharmaceutical company, for $2.2 billion. The deal was announced in January 2026.  The acquisition includes ozureprubart, a long-acting anti-immunoglobulin E…

The latest from CDMOs, CMOs, and suppliers featuring CordenPharma, Flamma, BioDuro, Cenra, Bora Pharmaceuticals, Upperton, Biologos, Coating Place and more.   Chemicals/Chemical API Manufacturing * CordenPharma in Peptide Lab Expansion* Flamma API Mfg Site Passes FDA Inspection * BioDuro, Cenra API Form JV for API…

A roundup of news from the large and mid-sized bio/pharmaceutical companies featuring Eli Lilly and Company, Sanofi, Daiichi Sankyo, Teva, Moderna, UCB, Alnylam, and Bavarian Nordic. Highlights below.   For the latest news roundup on small and Emerging Pharma…

The latest from small and Emerging Pharma companies featuring Atrium Therapeutics, BioAtla, Gyre Therapeutics, Kivu Bioscience, Portal Innovations, Theravance Biopharma and XyloCor.  For news on the large and mid-sized bio/pharmaceutical companies, see Global Briefs.  …

Novartis has announced plans to establish a new 46,000-square-foot radioligand therapy (RLT) manufacturing site in Denton, Texas. This purpose-built RLT site will be the company’s fifth in the US and first manufacturing…

AbbVie has announced a new $380-million investment to build two new active pharmaceutical ingredient (API) manufacturing facilities at its current North Chicago, Illinois, campus. The facilities are the first in AbbVie’s…

Gilead Sciences has agreed to acquire Arcellx, a bio/pharmaceutical company focused on oncology, for $7.8 billion.   Kite, a subsidiary of Gilead Sciences, and Arcellx have an existing collaboration to co-develop and co-commercialize…

The latest from CDMOs, CMOs, and suppliers featuring Olon/Zymvol, Avid Bioservices and Univar Solutions.   Chemicals/Chemical API Manufacturing * Olon, Zymvol in Biocatalysis Pact Biologics Manufacturing * Avid Bioservices Opens New Early-Phase Center of Excellence Formulation Development/Drug Product Manufacturing * Univar Solutions Chosen as Ingredion Pharma…